Cadrenal Therapeutics (CVKD) proposes sale of 107 common shares

Rhea-AI Filing Summary

Cadrenal Therapeutics, Inc. (CVKD) filed a Form 144 notifying the proposed sale of 107 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $1517.26. The planned sale is listed for 10/06/2025 and the shares were originally acquired as founders' shares on 05/17/2022.

The filing also lists multiple recent Rule 10b5-1 sales by the same person between 08/27/2025 and 10/01/2025, totaling substantial share volumes (for example 10,900 shares on 09/25/2025). The filer certifies no undisclosed material adverse information and indicates reliance on a trading plan where applicable.

Positive

• Use of 10b5-1 trading plan indicates sales were pre‑planned, reducing timing uncertainty
• Filer disclosed acquisition details (founders' shares from 05/17/2022), improving transparency

Negative

• Significant recent insider sales including 10,900 shares on 09/25/2025 could increase share supply
• Proposed sale on 10/06/2025 adds to near-term insider selling pressure

Insights

Insider Transactions Analyst

Insider selling appears structured under a trading plan; recent large 10b5-1 sales increased liquidity.

The notice records a proposed sale of 107 shares valued at $1517.26 on 10/06/2025, and multiple 10b5-1 executed sales totaling multi-thousand share lots in late 09/2025. Structured plans like 10b5-1 are used to execute pre-set sales while reducing timing risk.

Key dependencies include the existence and adoption date of the 10b5-1 plan and market pricing on 10/06/2025. Monitor aggregate insider sales volumes versus outstanding shares and any future notices for plan termination or additional sales within the next 30–90 days.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	107	1517.26	2046854	10/06/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/17/2022	Founders Shares	Issuer			107	05/17/2022	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for MATTHEW SZOT 822 A1A North, Suite 306 Ponte Vedra FL 32082	Common	10/01/2025	1700	23786.06
10b5-1 Sales for MATTHEW SZOT 822 A1A North, Suite 306 Ponte Vedra FL 32082	Common	09/29/2025	100	1400.00
10b5-1 Sales for MATTHEW SZOT 822 A1A North, Suite 306 Ponte Vedra FL 32082	Common	09/25/2025	10900	153182.06
10b5-1 Sales for MATTHEW SZOT 822 A1A North, Suite 306 Ponte Vedra FL 32082	Common	09/24/2025	1500	20992.95
10b5-1 Sales for MATTHEW SZOT 822 A1A North, Suite 306 Ponte Vedra FL 32082	Common	08/28/2025	400	5600.00
10b5-1 Sales for MATTHEW SZOT 822 A1A North, Suite 306 Ponte Vedra FL 32082	Common	08/27/2025	1600	22392.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the CVKD Form 144 disclose?

The filing discloses a proposed sale of 107 common shares valued at $1517.26 through Morgan Stanley on 10/06/2025 and recent 10b5-1 sales.

Who is selling CVKD shares under this Form 144?

The notice identifies the seller as the person for whose account the securities are to be sold; recent 10b5-1 sales are attributed to MATTHEW SZOT at the provided address.

Were the shares originally acquired as compensation or founders' equity?

The 107 shares to be sold were acquired as Founders Shares from the issuer on 05/17/2022.

Have there been recent insider sales for CVKD?

Yes. The filing lists 10b5-1 sales between 08/27/2025 and 10/01/2025, including 10,900 shares sold on 09/25/2025.

Does the filer state any undisclosed material information?

By signing, the filer represents they do not know any material adverse information that has not been publicly disclosed.